An open, randomized, parallel-group, multicentre, phase IIIB study to evaluate the efficacy of Symbicort Turbuhaler Single Inhaler Therapy (SiT), given as a low maintenance dose once or twice daily plus as needed, compared to a higher maintenance dose of Symbicort Turbuhaler given twice daily plus Oxis Turbuhaler as needed during 24 weeks in asthmatic patients

Study identifier:LD-039-0003

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An open, randomized, parallel-group, multicentre, phase IIIB study to evaluate the efficacy of Symbicort Turbuhaler Single Inhaler Therapy (SiT), given as a low maintenance dose once or twice daily plus as needed, compared to a higher maintenance dose of Symbicort Turbuhaler given twice daily plus Oxis Turbuhaler as needed during 24 weeks in asthmatic patients

Medical condition

respiratory system

Phase

Phase 3

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Interventional

Age

Date

Study Start Date: 01 Feb 2003

Primary Completion Date: -

Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Dec 2013 by AstraZeneca

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions

Documents available

CSR-LD-039-0003.pdf
Download
Trial Results Summaries
Available here